8-K: Indaptus Therapeutics Appoints David Natan to Board

Indaptus Therapeutics, Inc. announced the appointment of financial expert David Natan to its Board of Directors and Audit Committee, increasing the board size to nine members.

Summary

• Indaptus Therapeutics, Inc. increased its Board of Directors from eight to nine members on January 8, 2026.
• David Natan was appointed as a Class II director, with his term expiring at the 2026 annual meeting of stockholders, at which point he will stand for election.
• Mr. Natan was designated by Mr. David E. Lazar, exercising a right under a securities purchase agreement dated December 22, 2025.
• He brings extensive experience as an executive, with a background in finance, including roles as President and CEO of Natan & Associates, LLC, CEO of ForceField Energy, Inc., and CFO of Pharma Net Development Group, Inc.
• Mr. Natan currently serves on the Board of Directors and chairs the Audit Committees of Sunshine Biopharma, Inc. (Nasdaq: SBFM) since February 2022, and FIEE, Inc. since April 2024.
• He was appointed as a member of the Audit Committee, replacing Mr. Avraham Ben-Tzvi, who will continue to serve as a director and be engaged as a paid consultant.
• The Board determined Mr. Natan is an independent director and meets NASDAQ's heightened independence standards for Audit Committee service.
• Mr. Natan will participate in the company's non-employee director compensation plan, effective April 2, 2023.

Sentiment

Score: 7

Explanation: The appointment of an experienced independent director with a strong financial background and public company experience is a positive step for corporate governance and financial oversight. The retention of the outgoing Audit Committee chair as a consultant also ensures continuity of expertise.

Positives

• The appointment of David Natan, an experienced financial executive with a strong background in public companies, is expected to strengthen the Board of Directors.
• Mr. Natan's appointment to the Audit Committee and his qualification as an independent director enhance corporate governance and compliance with NASDAQ listing standards.
• The retention of Mr. Avraham Ben-Tzvi as a director and paid consultant ensures the company continues to benefit from his expertise while transitioning Audit Committee leadership.

Future Outlook

David Natan will serve as a Class II director until the 2026 annual meeting of stockholders, at which point he will stand for election by the shareholders. The company intends to engage Mr. Avraham Ben-Tzvi as a paid consultant.

Management Comments

• Mr. Natan's extensive experience as an executive, his background in finance, and his exposure to public companies qualifies him to be on our Board.

Industry Context

This appointment reflects a common practice among public companies to strengthen corporate governance and financial oversight by adding experienced independent directors, particularly those with a strong background in finance and public company reporting, which is crucial for a biotechnology firm like Indaptus Therapeutics navigating complex regulatory and financial landscapes.

Comparison to Industry Standards

• The appointment of an independent director with extensive financial and public company experience, including prior roles as CFO and audit committee chair, aligns with best practices in corporate governance for publicly traded biotechnology companies.
• While no specific comparable companies or projects are mentioned in the filing, such appointments are standard for enhancing financial reporting integrity and strategic oversight, similar to governance structures seen in peers within the Nasdaq Capital Market.

Management Changes

Corporate Governance

Related Party Transactions

• David Natan was appointed as a nominee designated by Mr. David E. Lazar in exercise of Mr. Lazar's right to recommend three individuals to the Board under a securities purchase agreement dated December 22, 2025.

Stakeholder Impact

• Shareholders: Enhanced corporate governance and financial oversight through the addition of an experienced independent director, potentially leading to improved investor confidence.

Next Steps

• David Natan will stand for election by shareholders at the 2026 annual meeting of stockholders.
• The Company intends to engage Mr. Avraham Ben-Tzvi as a paid consultant.

Key Dates

Recommendation

The appointment of an experienced independent director to the board and audit committee is a positive governance development, enhancing oversight and compliance. However, this is a routine corporate governance update and does not provide new information on the company's operational performance, financial health, or strategic direction that would warrant a change in investment recommendation. Investors should hold and await further operational or financial updates.

Keywords

Indaptus Therapeutics, INDP, Board of Directors, David Natan, Audit Committee, Corporate Governance, Director Appointment, NASDAQ Compliance, Financial Executive